Cytokinetics Completes $55.0 Million Series C Financing

South San Francisco, CA - November 27, 2000

Cytokinetics, Inc., a privately held biotechnology and informatics company focused on cytoskeletal drug discovery and cellular bioinformatics, announced today that it has completed a Series C Preferred Stock financing totaling $55.0 million. Leading the financing was new investor CSFB Private Equity. Other new investors include Alta Partners and Lombard Odier & Cie. Previous investors Mayfield Fund, Sevin Rosen Funds, Vulcan Ventures, Inc. and others also participated.

“This financing represents an important validation of cytoskeletal pharmacology as a unique and important platform for drug discovery and informatics,” stated James Sabry, M.D., Ph.D., Cytokinetics’ President and Chief Executive Officer. “With the support of these investors, Cytokinetics is well positioned to capitalize on our promising drug discovery programs as well as to advance the development and commercialization of the CytometrixTM platform.

“In this post-genomics era, the integration of functional biology and applied bioinformatics holds great promise for the discovery of novel therapeutics,” commented Michael Schmertzler, Managing Director and Co-Head of the US Fund at CSFB Private Equity. “Cytokinetics holds critical pieces of this synergistic puzzle. We are pleased to be part of this team.”

About Cytokinetics
Founded in 1998, Cytokinetics is dedicated to the discovery of an entirely novel class of therapeutic compounds utilizing the Company’s expertise in the newly emerging field of cytoskeletal pharmacology. The cytoskeleton is a complex, dynamic framework that impacts all aspects of cell function including cell division, cell motility, intracellular transport and regulation of cell polarity and organization. The Company combines its drug discovery effort with its proprietary Cytometrix™ bioinformatics technologies in order to provide a product line of lead development and target validation informatics technologies. The Company is currently pursuing multiple therapeutic programs focused on the identification of novel pharmaceuticals against cancer, cardiovascular and infectious diseases and is planning an upcoming beta release of Cytometrix™ services and informatics tools designed to measure and interpret cellular physiology. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

About CSFB Private Equity
CSFB Private Equity, the global private equity arm of Credit Suisse Group, is one of the largest managers of alternative assets in the world, with over $25 billion in funds under management. CSFB Private Equity is comprised of investment funds that focus on domestic and international leveraged buyouts and other private equity investments, mezzanine investments, real estate investments, venture capital investments, investments in distressed debt securities and investments in other funds. CSFB Private Equity includes the family of DLJ Merchant Banking funds, DLJ Phoenix funds and the Sprout funds. CSFB Private Equity maintains offices in New York, London, Buenos Aires, Hong Kong, Los Angeles, Moscow and São Paulo.

Statements in this news release that are not strictly historical are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. There can be no assurance that Cytokinetics will be able to develop or commercialize its products. The actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the Company's operations and business environment. These risks are more fully described from time to time in disclosures made by the Company.